Comparative Pharmacology
Head-to-head clinical analysis: ETHCHLORVYNOL versus NOLUDAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHCHLORVYNOL versus NOLUDAR.
ETHCHLORVYNOL vs NOLUDAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethchlorvynol is a sedative-hypnotic with central nervous system depressant effects. Its exact mechanism is unknown, but it may potentiate GABA activity or depress neuronal excitability.
Barbiturate that enhances GABA-A receptor activity by prolonging chloride channel opening, leading to CNS depression.
500 mg to 1 g orally at bedtime as needed for insomnia.
250-500 mg orally at bedtime, with a maximum dose of 1000 mg daily.
None Documented
None Documented
10-25 minutes (initial rapid distribution phase); terminal elimination half-life approximately 4-6 hours in adults (prolonged in liver disease due to reduced clearance).
Clinical Note
moderateEthchlorvynol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluticasone propionate."
Clinical Note
moderateEthchlorvynol + Clemastine
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clemastine."
Clinical Note
moderateEthchlorvynol + Venlafaxine
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Venlafaxine."
Clinical Note
moderate25-35 hours
Renal: <1% unchanged; Hepatic metabolism to inactive conjugates; Fecal: minimal. Approximately 90% of a dose is excreted in urine as glucuronide conjugates within 24 hours.
Primarily renal as metabolites; <5% unchanged. Biliary/fecal elimination is negligible.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic
Ethchlorvynol + Nefazodone
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nefazodone."